Having trouble accessing articles? Reset your cache.

Patient access, antisense oligo key to Angelman deal for Ultragenyx

Ultragenyx's partnership and option deal with Angelman syndrome company GeneTX delivers two components key to success in the rare disease: a candidate that targets the root cause of the disease, and a direct link to patients.

The companies teamed up to advance GeneTX Biotherapeutics LLC's preclinical antisense oligonucleotide, GTX-102, into clinical development, and Ultragenyx Pharmaceuticals Inc. (NASDAQ:RARE)

Read the full 568 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE